AtriCure (ATRC) Stock Analysis & AI Equity Report

Medical - Instruments & Supplies USD Explore free reports

AtriCure (ATRC) overview

AtriCure (ATRC) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 535m and operating profit of USD -9.4m; the year-end share price was 39.56 USD and market capitalisation was USD 1,970m. AtriCure is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get AtriCure's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 492mFY 2025
Share price39.56 USDFY 2025 year end
RevenueUSD 535mFY 2025
Operating profitUSD -9.4mFY 2025
Net earningsUSD -11.4mFY 2025
Market capitalisationUSD 1,970mFY 2025 year end

About AtriCure

AtriCure develops surgical treatments and therapies for atrial fibrillation, left atrial appendage management, and post-operative pain. Its cardiac ablation and appendage-management products are used by physicians in open-heart and minimally invasive procedures. CryoICE cryoSPHERE and cryoXT probes provide temporary nerve-block pain relief after cardiac, thoracic, and amputation surgeries. AtriCure sells to medical centers directly and through distributors.

Generate the AtriCure report

AtriCure is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for AtriCure and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on AtriCure

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.